Andrew Thomas

Andrew Thomas is a managing partner of Helvetica Capital and a founder of the IPSO Group. Previously, he was a founding Executive Board member of the Swiss Industry Science Fund (SISF) and Global Head of Medicinal Chemistry at Roche where he was responsible for the development of small molecule drugs in different therapeutic areas including oncology. Andrew holds a PhD in Chemistry from the University of St. Andrews.